Recombinant Adeno-associated virus (rAAV) is the viral vector of choice for many ground-breaking research and clinical applications. The vector is being utilized in gene therapy to treat rare genetic diseases, as well as clinical studies for treating a range of diseases with broader indications. This means global demand for high quality rAAV manufacturing is escalating. In this new eBook created through a collaboration between experts at Sartorius and the University of Nantes, we explore various aspects of upstream rAAV production. The authors discuss the challenges that rAAV experts face and propose some of the best practice solutions they have employed to overcome them. Through a series of opinion-led and case study articles, you’ll learn how combining new technology such as high throughput mini bioreactors and Design of Experiments (DOE) software can help rapidly optimize rAAV production.